Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial.

MLA

Mukherjee, Somnath, et al. “Efficacy of Early PET-CT Directed Switch to Carboplatin and Paclitaxel Based Definitive Chemoradiotherapy in Patients with Oesophageal Cancer Who Have a Poor Early Response to Induction Cisplatin and Capecitabine in the UK: A Multi-Centre Randomised Controlled Phase II Trial.” EClinicalMedicine, vol. 61, June 2023, p. 102059. EBSCOhost, https://doi.org/10.1016/j.eclinm.2023.102059.

APA

Mukherjee, S., Hurt, C. N., Adams, R., Bateman, A., Bradley, K. M., Bridges, S., Falk, S., Griffiths, G., Gwynne, S., Jones, C. M., Markham, P. J., Maughan, T., Nixon, L. S., Radhakrishna, G., Roy, R., Schoenbuchner, S., Sheikh, H., Spezi, E., Hawkins, M., & Crosby, T. D. L. (2023). Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial. EClinicalMedicine, 61, 102059. https://doi.org/10.1016/j.eclinm.2023.102059

Chicago

Mukherjee, Somnath, Christopher N Hurt, Richard Adams, Andrew Bateman, Kevin M Bradley, Sarah Bridges, Stephen Falk, et al. 2023. “Efficacy of Early PET-CT Directed Switch to Carboplatin and Paclitaxel Based Definitive Chemoradiotherapy in Patients with Oesophageal Cancer Who Have a Poor Early Response to Induction Cisplatin and Capecitabine in the UK: A Multi-Centre Randomised Controlled Phase II Trial.” EClinicalMedicine 61 (June): 102059. doi:10.1016/j.eclinm.2023.102059.